• Molecular NameFluvoxamine
  • SynonymFluvoxamina [INN-Spanish]; fluvoxamine; Fluvoxamine maleate; fluvoxamine-CR; Fluvoxaminum [INN-Latin]
  • Weight318.339
  • Drugbank_IDDB00176
  • ACS_NO54739-18-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.14
  • pka8.7
  • LogD (pH=7, predicted)1.51
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.6
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.45
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds10
  • TPSA56.84
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antidepressant which functions as a selective serotonin reuptake inhibitor and is predominantly used to treat obsessive–compulsive disorder.
  • Absorption_value90.0
  • Absorption (description)Fluvoxamine is readily and completely absorbed after oral administration with peak plasma concentrations occurring after about 2 to 8 h (prolonged with enteric-coated tablets to 4 to 12 h).
  • Caco_2N/A
  • Bioavailability53.0
  • Protein binding77.0
  • Volume of distribution (VD)25 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHowever, it undergoes significant first-pass metabolism and bioavailability is about 53%. It is widely distributed. Fluvoxamine undergoes extensive metabolism in the liver mainly by oxidative deamination, oxidative demethylation and N-acetylation to produce a number of inactive metabolites.
  • Half life17~22 h, after repeated dosing.
  • ExcretionThe parent and its metabolites (11 in total detected) have been recovered in urine; less than 4% as the parent drug. Fluvoxamine appears to inhibit the following cytochrome P450 isoenzymes; 1A2, 2C9, 3A4. It is distributed into breast milk.
  • Urinary ExcretionN/A
  • Clerance3 L/min (oral); 1.5 L/min (intravenous).
  • ToxicitySide effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=282 (ip)